DT01 Rec'd PCT/PTT 2 1 JAN 2003

## Amendments to the Claims:

## Listing of Claims:

Claim 1 (original): Use A method consisting of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of formula l

(1) or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of anaplastic thyroid carcinomas.

Claim 2 (original): The use A method consisting of 4-(4-methylpiperazin-1-ylmethyl)-N-[4methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of formula I or a pharmaceutically acceptable salt thereof in the treatment of anaplastic thyroid carcinomas.

Claim 3 (original): A method of treating humans suffering from anaplastic thyroid carcinoma which comprises administering to a said human in need of such treatment a dose, effective against said disease, of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3yl)pyrimidin-2-ylamino)phenyl]-benzamide or a pharmaceutically acceptable salt thereof.

Claim 4 (original): A method according to claim 3 wherein a daily dose of 50 to 600 mg of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]benzamide of formula I is administered to an adult.

Claim 5 (original): A method according to claim 3 wherein the monomethanesulfonate salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]benzamide of formula I is administered.

Claim 6 (original): A method according to claim 3 which comprises administering a pharmaceutically effective amount of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of formula I or a pharmaceutically acceptable salt thereof to the human subject once daily for a period exceeding 3 months.

Claim 7 (currently amended): Use of A method according to any of claim 1 to 6claim 1 wherein 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-yl-amino)phenyl]-benzamide of formula I is in mesylate salt form and in the beta crystal form thereof.

Claim 8 (currently amended): Use or A method according to any one of claims 1 to 7 claim 1 wherein the anaplastic thyroid carcinoma is harboring mutated p53.